MX2010001080A - Pirrolidin-aril-eteres como antagonistas de receptor de nk3. - Google Patents
Pirrolidin-aril-eteres como antagonistas de receptor de nk3.Info
- Publication number
- MX2010001080A MX2010001080A MX2010001080A MX2010001080A MX2010001080A MX 2010001080 A MX2010001080 A MX 2010001080A MX 2010001080 A MX2010001080 A MX 2010001080A MX 2010001080 A MX2010001080 A MX 2010001080A MX 2010001080 A MX2010001080 A MX 2010001080A
- Authority
- MX
- Mexico
- Prior art keywords
- lower alkyl
- halogen
- cyano
- hydrogen
- substituted
- Prior art date
Links
- -1 Pyrrolidine aryl-ether Chemical class 0.000 title abstract 3
- 102000002003 Neurokinin-3 Receptors Human genes 0.000 title abstract 2
- 108010040716 Neurokinin-3 Receptors Proteins 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 2
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
La invención se refiere a un compuesto de la fórmula general (Ver fórmula I) en donde Ar1 es arilo o un heteroarilo de cinco o seis eslabones; Ar2 es arilo o un heteroarilo de cinco o seis eslabones; R1 es hidrógeno, halógeno, alquilo inferior, alcoxi inferior, alquilo inferior sustituido por halógeno, alcoxi inferior sustituido por halógeno, S-alquilo inferior, -S(O)2- alquilo interior, -S(O)2-di(alquilo inferior)-amino, (CH2)qR, ciano, amino, mono- o di-(alquilo inferior)-amino, NHC(O)alquilo inferior, cicloalquilo o es un heteroarilo de cinco eslabones, opcionalmente sustituido por alquilo interior; en el que R es ciano, di(alquilo inferior)-amino o pirrolidin-1-ilo; R2 es hidrógeno, halógeno, alquilo interior, alquilo inferior sustituido por halógeno o ciano; R3 es hidrógeno o alquilo interior o CH2OH; R4 es hidrógeno, halógeno, alquilo inferior, alquilo interior sustituido por halógeno o ciano; n es 1, 2 ó 3; en caso de que n sea 2 ó 3, R1 puede ser igual o diferente; o es 1, 2 ó 3; en caso de que o sea 2 ó 3, R2 puede ser igual o diferente; p es 1, 2 6 3; en caso de que p sea 2 6 3, R4 puede ser igual o diferente; q es 1 ó 2; o a una sal farmacéuticamente activa del mismo; incluidas todas las formas estereoisoméricas, todos los diaestereoisómeros y enantiómeros individuales del compuesto de la fórmula (I) así como las mezclas racémicas y no racémicas de los mismos. Se ha encontrado que los compuestos presentes son antagonistas potencialmente fuertes del receptor de la NK-3 para el tratamiento de la depresión, el dolor, la psicosis, la enfer10 medad de parkinson, la esquizofrenia, la ansiedad y el trastorno de hiperactividad con déficit de atención (ADHD).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07113942 | 2007-08-07 | ||
| PCT/EP2008/059908 WO2009019163A1 (en) | 2007-08-07 | 2008-07-29 | Pyrrolidine aryl-ether as nk3 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010001080A true MX2010001080A (es) | 2010-03-01 |
Family
ID=39865446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010001080A MX2010001080A (es) | 2007-08-07 | 2008-07-29 | Pirrolidin-aril-eteres como antagonistas de receptor de nk3. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8012998B2 (es) |
| EP (1) | EP2185540B1 (es) |
| JP (1) | JP2010535733A (es) |
| KR (1) | KR101167774B1 (es) |
| CN (1) | CN101778837A (es) |
| AR (1) | AR067808A1 (es) |
| AT (1) | ATE517100T1 (es) |
| AU (1) | AU2008285718A1 (es) |
| BR (1) | BRPI0815658A2 (es) |
| CA (1) | CA2695211A1 (es) |
| CL (1) | CL2008002293A1 (es) |
| ES (1) | ES2367464T3 (es) |
| IL (1) | IL203363A (es) |
| MX (1) | MX2010001080A (es) |
| PE (1) | PE20090898A1 (es) |
| RU (1) | RU2010106974A (es) |
| TW (1) | TW200916456A (es) |
| WO (1) | WO2009019163A1 (es) |
| ZA (1) | ZA201000676B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE519738T1 (de) * | 2007-08-22 | 2011-08-15 | Hoffmann La Roche | Pyrrolidinarylether als nk3-rezeptorantagonisten |
| WO2010086259A1 (en) | 2009-01-30 | 2010-08-05 | F. Hoffmann-La Roche Ag | Piperidine derivatives as nk3 receptor antagonists |
| US8318759B2 (en) * | 2009-02-18 | 2012-11-27 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives as NK3 receptor antagonists |
| US8394834B2 (en) | 2009-08-25 | 2013-03-12 | Hoffman-La Roche Inc. | Pyrrolidines as NK3 receptor antagonists |
| EP2491026A1 (en) * | 2009-10-20 | 2012-08-29 | Pfizer Inc. | Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators |
| US8507535B2 (en) | 2010-07-07 | 2013-08-13 | Hoffmann-La Roche Inc. | Methyl-pyrrolidine ether derivatives |
| US10112939B2 (en) | 2014-08-21 | 2018-10-30 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
| MD3344248T2 (ro) | 2015-09-02 | 2022-10-31 | Trevena Inc | Aza-heterociclic cu 6 elemente conținând compuși de modulare a receptorului delta-opioid, metode de utilizare și fabricare a acestora |
| WO2017072629A1 (en) | 2015-10-29 | 2017-05-04 | Cadila Healthcare Limited | Pharmaceutical combination of nk3 receptor antagonist and biguanides |
| CN105399661A (zh) * | 2015-12-14 | 2016-03-16 | 华东师范大学 | 2,6-二溴甲基吡啶的制备方法 |
| EP3456716A4 (en) * | 2016-05-09 | 2019-11-06 | Nippon Soda Co., Ltd. | RINGFUL AMID CONNECTION AND PESTICIDES |
| KR102662065B1 (ko) | 2017-02-17 | 2024-05-07 | 트레베나, 인코포레이티드. | 7-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법 |
| WO2018152293A1 (en) | 2017-02-17 | 2018-08-23 | Trevena, Inc. | 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
| WO2021030335A1 (en) * | 2019-08-12 | 2021-02-18 | Millendo Therapeutics, Inc. | A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU506399B2 (en) * | 1975-12-30 | 1980-01-03 | Showa Denko Kabushiki Kaisha | 3-(2-aryl-2-propyl) ureas |
| IN148482B (es) | 1977-06-03 | 1981-03-07 | Pfizer | |
| GB9321557D0 (en) * | 1992-11-03 | 1993-12-08 | Zeneca Ltd | Carboxamide derivatives |
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| DE69428913T2 (de) | 1993-12-29 | 2002-05-29 | Merck Sharp & Dohme Ltd., Hoddesdon | Substituierte morpholinderivate und ihre verwendung als arzneimittel |
| TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| GB9714129D0 (en) * | 1997-07-04 | 1997-09-10 | Pfizer Ltd | Azetidines |
| US5972938A (en) * | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
| EP1192952A3 (en) | 2000-09-28 | 2003-03-26 | Pfizer Products Inc. | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist |
| US6531597B2 (en) | 2001-02-13 | 2003-03-11 | Hoffmann-La Roche Inc. | Process for preparation of 2-phenyl acetic acid derivatives |
| CA2487688A1 (en) * | 2002-05-31 | 2003-12-11 | Takeda Pharmaceutical Company Limited | Piperidine derivative, process for producing the same, and use |
| JP4490421B2 (ja) | 2003-07-03 | 2010-06-23 | エフ．ホフマン−ラ ロシュ アーゲー | 統合失調症を処置するデュアルｎｋ１／ｎｋ３アンタゴニスト |
| CA2540061A1 (en) * | 2003-09-30 | 2005-04-14 | Merck & Co., Inc. | Phenyl pyrrolidine ether tachykinin receptor antagonists |
| JPWO2005068427A1 (ja) * | 2004-01-14 | 2007-09-06 | 武田薬品工業株式会社 | カルボキサミド誘導体およびその用途 |
| US7138423B2 (en) * | 2004-07-20 | 2006-11-21 | Bristol-Myers Squibb Company | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists |
| KR100939347B1 (ko) | 2005-07-20 | 2010-01-29 | (주)카이로드 | 광학적으로 순수한 (ｓ)-3-히드록시 피롤리딘의 제조방법 |
-
2008
- 2008-07-29 CN CN200880102376A patent/CN101778837A/zh active Pending
- 2008-07-29 CA CA2695211A patent/CA2695211A1/en not_active Abandoned
- 2008-07-29 BR BRPI0815658-1A2A patent/BRPI0815658A2/pt not_active IP Right Cessation
- 2008-07-29 KR KR1020107004881A patent/KR101167774B1/ko not_active Expired - Fee Related
- 2008-07-29 MX MX2010001080A patent/MX2010001080A/es active IP Right Grant
- 2008-07-29 AU AU2008285718A patent/AU2008285718A1/en not_active Abandoned
- 2008-07-29 RU RU2010106974/04A patent/RU2010106974A/ru unknown
- 2008-07-29 WO PCT/EP2008/059908 patent/WO2009019163A1/en not_active Ceased
- 2008-07-29 AT AT08786547T patent/ATE517100T1/de active
- 2008-07-29 EP EP08786547A patent/EP2185540B1/en not_active Not-in-force
- 2008-07-29 JP JP2010519428A patent/JP2010535733A/ja active Pending
- 2008-07-29 ES ES08786547T patent/ES2367464T3/es active Active
- 2008-08-04 US US12/185,157 patent/US8012998B2/en not_active Expired - Fee Related
- 2008-08-04 CL CL2008002293A patent/CL2008002293A1/es unknown
- 2008-08-05 PE PE2008001308A patent/PE20090898A1/es not_active Application Discontinuation
- 2008-08-05 AR ARP080103406A patent/AR067808A1/es unknown
- 2008-08-06 TW TW097129930A patent/TW200916456A/zh unknown
-
2010
- 2010-01-18 IL IL203363A patent/IL203363A/en not_active IP Right Cessation
- 2010-01-28 ZA ZA201000676A patent/ZA201000676B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200916456A (en) | 2009-04-16 |
| KR20100045502A (ko) | 2010-05-03 |
| EP2185540A1 (en) | 2010-05-19 |
| AR067808A1 (es) | 2009-10-21 |
| CA2695211A1 (en) | 2009-02-12 |
| CN101778837A (zh) | 2010-07-14 |
| RU2010106974A (ru) | 2011-09-20 |
| AU2008285718A1 (en) | 2009-02-12 |
| PE20090898A1 (es) | 2009-07-13 |
| US8012998B2 (en) | 2011-09-06 |
| ATE517100T1 (de) | 2011-08-15 |
| ZA201000676B (en) | 2010-10-27 |
| KR101167774B1 (ko) | 2012-07-24 |
| US20090042896A1 (en) | 2009-02-12 |
| WO2009019163A1 (en) | 2009-02-12 |
| CL2008002293A1 (es) | 2009-05-29 |
| BRPI0815658A2 (pt) | 2015-02-18 |
| JP2010535733A (ja) | 2010-11-25 |
| IL203363A (en) | 2013-03-24 |
| EP2185540B1 (en) | 2011-07-20 |
| ES2367464T3 (es) | 2011-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010001080A (es) | Pirrolidin-aril-eteres como antagonistas de receptor de nk3. | |
| MX2010001774A (es) | Pirrolidin aril-eteres como antagonistas de receptores de nk3. | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| CY1114702T1 (el) | Νεοι εναnτιομερως καθαροι βητα αγωνιστες, μεθοδος για την παραγωγη τους και χρηση αυτων ως φαρμακων | |
| SE0303180D0 (sv) | Novel compounds | |
| SE0302232D0 (sv) | Novel Compounds | |
| MXPA04003007A (es) | Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades. | |
| MX2009008465A (es) | Nuevas 2-aminooxazolinas como ligandos de taar1. | |
| MX2009009121A (es) | Aminoamidas como antagonistas de orexina. | |
| IL192253A0 (en) | Substituted cyclohexylmethyl derivatives | |
| MX2009009384A (es) | Malonamidas como antagonistas de orexina. | |
| HRP20080175T3 (hr) | Supstituirani 2-aminotetrtalini, namijenjeni preventivnom liječenju parkinsonove bolesti | |
| MXPA05010816A (es) | Derivados de 4-(4- (heterociclilalcox}fenil)- 1-(heterociclil- carbonil) piperidina y compuestos relacionados como antagonistas de h3 de la histamina para el tratamiento de enfermedades neurologicas tales como alzheimer. | |
| IL202236A0 (en) | Prolinamide derivatives as nk3 antagonists | |
| PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
| MX2015014353A (es) | Derivados de 2-fenil- o 2-hetaril-imidazol[1,2-a]piridina. | |
| MX2016016488A (es) | Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar). | |
| AR068467A1 (es) | Compuestos de nicotinamida sustituida y sus usos en medicamentos | |
| ES2378594T8 (es) | Moduladores de piperidinilo y piperazinilo de la gamma-secretasa | |
| MX2009010727A (es) | Heterociclos como antagonistas de orexina. | |
| MX2012001799A (es) | Derivados de pirrolidina como antagonistas del receptor de neuroquinona 3 (nk3). | |
| EA201170736A1 (ru) | Синтез и новые солевые формы (r)-3-((e)-2-(пирролидин-3-ил)винил)-5-(тетрагидропиран-4-илокси) пиридина | |
| NZ592478A (en) | Process for synthesis of amino-methyl tetraline derivatives | |
| MX2012006293A (es) | Derivados de pirrolidina como antagonista del receptor nk-3. | |
| EA200701856A1 (ru) | Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |